424 related articles for article (PubMed ID: 15716077)
1. Stage conversion of Toxoplasma gondii RH parasites in mice by treatment with atovaquone and pyrrolidine dithiocarbamate.
Djurković-Djaković O; Nikolić A; Bobić B; Klun I; Aleksić A
Microbes Infect; 2005 Jan; 7(1):49-54. PubMed ID: 15716077
[TBL] [Abstract][Full Text] [Related]
2. Combined effect of atovaquone and pyrrolidine dithiocarbamate in the treatment of acute murine toxoplasmosis.
Djurković-Djaković O; Nikolić A; Bobić B; Klun I
Chemotherapy; 2004 Jun; 50(3):155-6. PubMed ID: 15272229
[No Abstract] [Full Text] [Related]
3. Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis.
Sordet F; Aumjaud Y; Fessi H; Derouin F
Parasite; 1998 Sep; 5(3):223-9. PubMed ID: 9772721
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii.
Romand S; Della Bruna C; Farinotti R; Derouin F
Antimicrob Agents Chemother; 1996 Sep; 40(9):2015-20. PubMed ID: 8878573
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil.
Alves CF; Vitor RW
Parasite; 2005 Jun; 12(2):171-7. PubMed ID: 15991831
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effect of clindamycin and atovaquone in acute murine toxoplasmosis.
Djurković-Djaković O; Nikolić T; Robert-Gangneux F; Bobić B; Nikolić A
Antimicrob Agents Chemother; 1999 Sep; 43(9):2240-4. PubMed ID: 10471572
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii.
Djurković-Djaković O; Milenković V; Nikolić A; Bobić B; Grujić J
J Antimicrob Chemother; 2002 Dec; 50(6):981-7. PubMed ID: 12461021
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the efficacy of atovaquone alone or in combination with azithromycin against acute murine toxoplasmosis.
Moshkani SK; Dalimi A
Vet Res Commun; 2000 Apr; 24(3):169-77. PubMed ID: 10836275
[TBL] [Abstract][Full Text] [Related]
9. The timing of sulfadiazine therapy impacts the reactivation of latent Toxoplasma infection in IRF-8-/- mice.
Jost C; Reiter-Owona I; Liesenfeld O
Parasitol Res; 2007 Nov; 101(6):1603-9. PubMed ID: 17846793
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.
Romand S; Pudney M; Derouin F
Antimicrob Agents Chemother; 1993 Nov; 37(11):2371-8. PubMed ID: 8285620
[TBL] [Abstract][Full Text] [Related]
11. IL-10 is not required to prevent immune hyperactivity during memory responses to Toxoplasma gondii.
Wille U; Nishi M; Lieberman L; Wilson EH; Roos DS; Hunter CA
Parasite Immunol; 2004 May; 26(5):229-36. PubMed ID: 15491472
[TBL] [Abstract][Full Text] [Related]
12. Loss of oral infectivity of tissue cysts of Toxoplasma gondii RH strain to outbred Swiss Webster mice.
Villard O; Candolfi E; Ferguson DJ; Marcellin L; Kien T
Int J Parasitol; 1997 Dec; 27(12):1555-9. PubMed ID: 9467741
[TBL] [Abstract][Full Text] [Related]
13. Effect of artesunate on Toxoplasma gondii: in vitro and in vivo studies.
El Zawawy LA
J Egypt Soc Parasitol; 2008 Apr; 38(1):185-201. PubMed ID: 19143130
[TBL] [Abstract][Full Text] [Related]
14. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii.
Araujo FG; Huskinson J; Remington JS
Antimicrob Agents Chemother; 1991 Feb; 35(2):293-9. PubMed ID: 2024964
[TBL] [Abstract][Full Text] [Related]
15. [Effects of atovaquone and astragalus combination on the treatment and IL-2, IL-12, IFN-γ levels on mouse models of acute toxoplasmosis].
Sönmez N; Büyükbaba Boral O; Kaşali K; Tekeli F
Mikrobiyol Bul; 2014 Oct; 48(4):639-51. PubMed ID: 25492659
[TBL] [Abstract][Full Text] [Related]
16. The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine.
Araujo FG; Lin T; Remington JS
J Infect Dis; 1993 Feb; 167(2):494-7. PubMed ID: 8421189
[TBL] [Abstract][Full Text] [Related]
17. Infection and immunity with the RH strain of Toxoplasma gondii in rats and mice.
Dubey JP; Shen SK; Kwok OC; Frenkel JK
J Parasitol; 1999 Aug; 85(4):657-62. PubMed ID: 10461945
[TBL] [Abstract][Full Text] [Related]
18. Vaccination of mice with Neospora caninum: response to oral challenge with Toxoplasma gondii oocysts.
Lindsay DS; Lenz SD; Dykstra CC; Blagburn BL; Dubey JP
J Parasitol; 1998 Apr; 84(2):311-5. PubMed ID: 9576504
[TBL] [Abstract][Full Text] [Related]
19. An ultrastructural study of the effect of treatment with atovaquone in brains of mice chronically infected with the ME49 strain of Toxoplasma gondii.
Ferguson DJ; Huskinson-Mark J; Araujo FG; Remington JS
Int J Exp Pathol; 1994 Apr; 75(2):111-6. PubMed ID: 8199003
[TBL] [Abstract][Full Text] [Related]
20. Toxoplasma gondii: in vitro and in vivo activities of the hydroxynaphthoquinone 2-hydroxy-3-(1'-propen-3-phenyl)-1,4-naphthoquinone alone or combined with sulfadiazine.
Ferreira RA; Oliveira AB; Ribeiro MF; Tafuri WL; Vitor RW
Exp Parasitol; 2006 Jun; 113(2):125-9. PubMed ID: 16458300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
